Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Dr Andrew A. Parsons
Director of Reciprocal Minds Limited & Chairman of Pharmasum Therapeutics AS
About the author:
Dr Andrew A Parsons initially trained as a Pharmacologist and Neuroscientist and has over 90 peer reviewed publications, several patents and contributed to Educational Books in Science and Medicine. His former scientific focus was in areas of neuroplasticity and neurodegeneration. He played key roles on individual projects from initial idea through development and the market place. Working across traditional organisational and cultural boundaries he was instrumental in creating External Innovation platforms within a large Pharma company. Through this he became interested the impact of Human Factors on operational processes. He is a member of the Pharmaceutical Special Interest group and an associate member of the Chartered Institute of Ergonomics and Human Factors.
He is the Director of Reciprocal Minds Limited which supports individuals and groups undergoing personal and professional development and challenges to health and wellbeing. He is the co-author of “Leading with Presence, what it is, why it matters and how to get it?” He is also the Chairman of Pharmasum Therapeutics AS, an early stage Biotech company.
Posts by Dr Andrew A. Parsons
Posted on February 6th, 2017 in Pharma R&D
A few years ago, I sat with some friends aiming to make predictions for the year ahead. Our goal was to see how close we could get, with a plan to review the following new year. We made several predictions for the world of science (more…)
Posted on December 28th, 2016 in Pharma R&D
As a professional, giving points away, or being involved in an “own goal,” must be quite an emotional roller coaster. However, in professional sports, the individual needs to get on with the game, put the error behind them, and move on to deal with the immediate situation. (more…)
Posted on December 19th, 2016 in Pharma R&D
It was interesting to note the article from Beth Snyder Bulik (1) that patient non-adherence to taking their prescribed medicines not only has a potential impact on their health and wellbeing, it also impacts the companies’ and healthcare providers’ bottom lines. (more…)
Posted on November 30th, 2016 in Pharma R&D
It is sad to hear about more paper retractions regarding early stage research with the R&D industry (1). Perhaps not surprisingly, the number of scientific publications being retracted for fraud and error has increased in recent years, at a faster rate than the rate of increased publications (2). (more…)